ResearcherFirst Affiliated Hospital of Zhengzhou UniversityNo recent work listed

Tingting Wang

ORCID-verified (high confidence)As of 10 November 2026

Matched on ORCID iD 0000-0002-6440-4827; OpenAlex author ID A5115602763.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Collaborators: 4

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper

Papers 2

ARNTL2 promotes pancreatic ductal adenocarcinoma progression through TGF/BETA pathway and is regulated by miR-26a-5p. Last author DOI 10.1038/s41419-020-02839-6 ↗
Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide… Co-author DOI 10.3892/or.2017.5580 ↗

Closest collaborators

The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Zhifang Wang · 1 shared paper, 2020
- Paper ARNTL2 promotes pancreatic ductal adenocarcinoma progression through TGF/BETA pathway and is regulated by miR-26a-5p. DOI 10.1038/s41419-020-02839-6 ↗
Guan Wang · 1 shared paper, 2017
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580 ↗
Shuang Liu · 1 shared paper, 2017
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580 ↗
Yubin Ge · 1 shared paper, 2017
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.